title: Venous thromboembolic disease in cancer. Optimisation of the use of antithrombotic agents.
abstract: Venous thromoboembolism is one of the most common complications in cancer patients and may have serious consequences. At present, most clinical oncologists report using thromboprophylaxis in less than 5% of patients. One of the possible reasons for this limited use is the lack of oncology specific guidelines. In effect, while there are excellent guidelines for optimising the use of antithrombotic agents to prevent and treat thromboembolism, they must be adapted to the concrete context of cancer patients. The present review explores how different situations affect cancer patients and their risk of developing venous thromboembolism (VTE), and evaluates the situations in which antithrombotic agents should be administered to treat and prevent VTE.
authors.affiliation: Servicio de Oncología Médica, Hospital General Universitario de Valencia, Valencia, Spain. camps_car@gva.es
authors.forename: C
authors.initials: C
authors.lastname: Camps
authors.forename: A
authors.initials: A
authors.lastname: Juárez
authors.forename: V
authors.initials: V
authors.lastname: Iranzo
authors.forename: J
authors.initials: J
authors.lastname: Garde
authors.forename: A
authors.initials: A
authors.lastname: Blasco
authors.forename: R
authors.initials: R
authors.lastname: Sirera
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects; D000990:Antithrombin III / Q000032:analysis; D002405:Catheterization, Central Venous / Q000009:adverse effects; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D004311:Double-Blind Method; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007103:Immobilization / Q000009:adverse effects; D008297:Male; D009369:Neoplasms / Q000097:blood*; D010447:Peptide Hydrolases / Q000032:analysis; D011183:Postoperative Complications / Q000209:etiology / Q000517:prevention & control; D011446:Prospective Studies; D011655:Pulmonary Embolism / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D012306:Risk; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control*; D019851:Thrombophilia / Q000188:drug therapy / Q000209:etiology*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood; D020246:Venous Thrombosis / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C046193:antithrombin III-protease complex; D000990:Antithrombin III; D010447:Peptide Hydrolases